A recent Federal Circuit decision shows why prior art analysis should focus on the full disclosure of a reference, not only the examples that receive the most attention.
In Board of Regents of the University of Texas System v. Boston Scientific Corp., the patent covered a composition containing a drug-releasing biodegradable polymer fiber. The patent owner asserted the claims against Boston Scientific’s drug-eluting coronary stents. A jury found infringement and rejected Boston Scientific’s anticipation defense, but the Federal Circuit reversed.
The anticipation issue centered on an earlier patent known as Song.
The patent owner’s expert focused on Song’s discussion of fibers that gradually released flavorants in chewing gum. But Song also expressly disclosed fibers that could release drugs and identified biodegradable polymers that could be used to form those fibers. The Federal Circuit considered the reference as a whole and concluded that it disclosed the limitations of the asserted claims.
The patent owner also relied on differences in how the therapeutic agent was released. The court found that those distinctions did not avoid anticipation because the claims did not require the particular release mechanism on which the patent owner relied. A technical difference may not distinguish an invention from the prior art when that difference is not reflected in the claim language.
The court separately found no infringement. The term “fiber” had been construed as a thread-like structure, but the infringement theory relied on a portion of the stent’s dried coating considered after it was artificially separated from the metal frame. The Federal Circuit concluded that the removed section of coating could not reasonably be treated as a thread-like fiber.
Practical takeaway: prior art should not be dismissed simply because its title, examples, or most familiar application appear to involve a different product. The full disclosure matters. For medical-device and drug-delivery patents, the claims should also identify the technical feature that actually separates the invention from earlier technology.
Federal Circuit opinion:
Board of Regents of the University of Texas System v. Boston Scientific Corp.
Decided July 27, 2026.
https://www.cafc.uscourts.gov/opinions-orders/24-2062.OPINION.7-27-2026_2728460.pdf







